Amphastar Pharmaceuticals, Inc.
Clinical trials sponsored by Amphastar Pharmaceuticals, Inc., explained in plain language.
A specialty pharmaceutical company focusing on generic and branded injectable products.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New insulin copycat could slash diabetes costs
Disease control CompletedThis study compares a new rapid-acting insulin (I004) to the approved NovoLog in 60 healthy adults. Researchers measure how fast the insulin enters the blood and how well it controls blood sugar using a special clamp technique. The goal is to show the two insulins work the same, …
Phase: PHASE2, PHASE3 • Sponsor: Amphastar Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New insulin copycat put to the test in healthy volunteers
Knowledge-focused CompletedThis study tested whether a new rapid-acting insulin (called I004) works the same as the approved insulin NovoLog. Sixty-nine healthy volunteers each received a single dose of both insulins at different times, and researchers measured how quickly the insulin entered the blood and…
Phase: PHASE2, PHASE3 • Sponsor: Amphastar Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC